Bifunctional peptide having capability to reduce inflammation and capability to facilitate differentiation of stem cells into chondrocytes and use thereof

Patent metadata

Field	Value
Publication number	US-11365218-B2
Application number	US-202016882648-A
Country	US
Kind code	B2
Filing date	May 25, 2020
Priority date	Mar 14, 2018
Publication date	Jun 21, 2022
Grant date	Jun 21, 2022

Abstract

Disclosed are a bifunctional peptide having the capability to reduce inflammation and the capability to facilitate differentiation of stem cells into chondrocytes and the use thereof. Advantageously, the bifunctional peptide is useful for the prevention or treatment of arthritis accompanied by inflammation and damage of cartilage tissue due to excellent effects of reducing inflammation and facilitating differentiation of stem cells into chondrocytes, can be easily applied to various surgical regenerative treatments including orthopedic treatments, and can shorten the treatment period.

First claim

What is claimed is:

1. A method for treating arthritis accompanied by damage of cartilage tissue, said method comprising promoting the differentiation of stem cells into chondrocytes by administering a peptide represented by the amino acid sequence of any one of SEQ ID NOS: 4 to 6 to a subject in need thereof, said peptide functioning to regenerate cartilage tissue, and to reduce arthritis inflammation.

2. The method according to claim 1 , wherein the peptide is prepared for injection or topical implantation.

3. The method according to claim 1 , wherein the peptide is administered at a dose of 0.001 to 1,000 mg per 1 kg of a body weight of the subject.

4. A method for treating arthritis accompanied by damage of cartilage tissue, said method, comprising promoting the differentiation of stem cells into chondrocytes by administering a biomaterial for treating arthritis comprising a peptide represented by the amino acid sequence of any one of SEQ ID NOS: 4 to 6 to a subject in need thereof, said peptide functioning to regenerate cartilage tissue, and to reduce arthritis inflammation.

5. The method according to claim 4 , wherein the biomaterial comprises any one selected from the group consisting of a barrier membrane, a porous scaffold, and an implant for bio-implant produced in the form of a gel.

6. The method according to claim 5 , wherein the barrier membrane comprises any one selected from the group consisting of collagen, chitosan, gelatin, polylactide, polylactide glycolide and polycaprolactone.

7. The method according to claim 5 , wherein the porous scaffold comprises any one selected from the group consisting of collagen, chitosan, gelatin, hyaluronic acid, alginic acid, chondroitin sulfate, polylactide, polylactide glycolide, and polycaprolactone.

8. The method according to claim 5 , wherein the gel comprises any one selected from the group consisting of collagen, chitosan, gelatin, hyaluronic acid, alginic acid, poloxamer, propylene glycol, propylene glycol alginate, chondroitin sulfate and glycosaminoglycan.

9. The method according to claim 4 , wherein the peptide is present at a dose of 1 to 50 mg per 1 g of the biomaterial.

Assignees

• Seoul Nat Univ R&Db Foundation
• Nano Intelligent Biomedical Eng Corporation Co Ltd

Inventors

• Park Yoon Jeong
• Chung Chong-Pyoung
• Lee Jue-Yeon

Classifications

• A61L2300/41

  Anti-inflammatory agents, e.g. NSAIDs · CPC title

• C12N2501/998

  Proteins not provided for elsewhere · CPC title

• A61L27/22

  Polypeptides or derivatives thereof {, e.g. degradation products} · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61L2300/25

  Peptides having up to 20 amino acids in a defined sequence · CPC title